{
    "nct_id": "NCT03739554",
    "official_title": "A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",
    "inclusion_criteria": "* CLL that is relapsed or refractory to BTK inhibitors and is on a stable dose of venetoclax\n* ECOG 0-2\n* Adequate bone marrow function\n* Adequate renal function\n* Adequate liver function\n* INR <=1.2 in patients not receiving chronic anticoagulation\n* At least 4 weeks from prior cytotoxic chemotherapy\n* At least 4 weeks from major surgery\n* Agree to practice effective contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known CLL involvement in CNS that is symptomatic and active\n* currently receiving radiotherapy, biological therapy, or any other investigational agents\n* Uncontrolled intercurrent illness\n* Pregnant or lactating\n* Known to be HIV-positive\n* Known active hepatitis B and/or hepatitis C infection",
    "miscellaneous_criteria": ""
}